TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07744763: A Multicenter, Open-label, Dose-escalation and Dose-expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Antitumor Activity of SYS6041 in Patients With Advanced Solid Tum

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 260 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07744763 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07744763 Rescue Dossier →